Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background. Definitive chemoradiotherapy represents the standard therapeutic approach for the management of locally advanced cervical cancer. Vitamin D plays an important role in the regulation of cellular growth and differentiation, immune system function, and the modulation of inflammatory processes. Hypovitaminosis D may be associated with the development of cervical cancer, whereas its impact on the effects of oncological treatment remains insufficiently elucidated. The aim of this study is to investigate the predictive significance of vitamin D in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy. Methods. This study is designed as a clinical, observational, prospective cohort study. Patients with locally advanced cervical cancer undergoing definitive chemoradiotherapy at the Clinic for Radiation Oncology, University Clinical Center Kragujevac, will be enrolled. Vitamin D concentrations will be measured before the initiation of treatment in both serum and cervical lavage samples. Baseline vitamin D levels will be analyzed in relation to treatment outcome and the occurrence of acute radiation toxicity. In addition, vitamin D concentrations will be evaluated in the context of clinical and morphological parameters, therapeutic response, and treatment-related toxicity. Expected Results. This study will enable an assessment of the actual significance of pretreatment vitamin D concentrations in serum and cervical lavage as a potential novel biomarker in relation to chemoradiosensitivity and/or chemoradioresistance of cervical cancer, as well as the response of organs at risk, in patients with locally advanced disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-80 lat
- •Potwierdzony histopatologicznie rak szyjki macicy
- •Zaawansowana choroba - stopień zaawansowania FIGO 2018 IIB do IVA
- •Dobry stan ogólny (skala ECOG 0-1)
- •Planowana chemio- i radioterapia
- •Podpisana zgoda na uczestnictwo w badaniu
- •Możliwość uczestniczenia w wizytach kontrolnych
✗ Disqualifies
- •Poniżej 18 roku życia
- •Ciąża lub karmienie piersią
- •Inny nowotwór w miednicy lub brzuchu (obecny lub przeszły)
- •Poprzednia chemioterapia lub radioterapia
- •Suplementacja witaminą D w ostatnim czasie
- •Przerwane leczenie onkologiczne
- •Niedochodze do zaplanowanych wizyt kontrolnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 4, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University Clinical Center Kragujevac
Kragujevac, Serbia
Trial contact
Marija Živković Radojević, MD, PhD, Radiation Oncologist
Neda Milosavljević, MD, PhD, Radiation Oncologist
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.